Suppr超能文献

接受厄他培南治疗的患者出现急性血小板增多症。

Acute Thrombocytosis in a Patient Treated with Ertapenem.

作者信息

Sarfo Edward K, Dziemianko Jennifer L, Chen Thomas, Iwaki Kosuke K

机构信息

Icahn School of Medicine at Mount Sinai, New York, USA.

NYC Health and Hospitals, Elmhurst Hospital Center, New York, USA.

出版信息

Eur J Case Rep Intern Med. 2024 Jan 25;11(2):004283. doi: 10.12890/2024_004283. eCollection 2024.

Abstract

UNLABELLED

Ertapenem, a carbapenem-type beta-lactam antibiotic, demonstrates broad-spectrum efficacy against a wide range of Gram-positive and Gram-negative bacteria, including aerobes and anaerobes. Importantly, it demonstrates resistance to virtually all beta-lactamases, including the extended spectrum beta-lactamases (ESBLs). Haematologic complications such as thrombocytosis, haemolysis, anaemia, and neutropenia are infrequent side effects associated with this drug. In this report, we present a rare case of ertapenem-induced thrombocytosis in a 62-year-old female patient who was admitted for a complicated urinary tract infection caused by .

LEARNING POINTS

Ertapenem was identified as the most likely cause of thrombocytosis.Discontinuing ertapenem normalised the platelet count.It is crucial for physicians to identify and address causes of thrombocytosis, particularly when related to medications, to avoid inadvertent complications and to ensure effective patient care.

摘要

未标注

厄他培南是一种碳青霉烯类β-内酰胺抗生素,对多种革兰氏阳性菌和革兰氏阴性菌具有广谱抗菌活性,包括需氧菌和厌氧菌。重要的是,它对几乎所有β-内酰胺酶都具有耐药性,包括超广谱β-内酰胺酶(ESBLs)。血小板增多、溶血、贫血和中性粒细胞减少等血液学并发症是与该药物相关的罕见副作用。在本报告中,我们介绍了一例62岁女性患者因复杂尿路感染入院,发生厄他培南诱导的血小板增多症的罕见病例。

学习要点

厄他培南被确定为血小板增多症最可能的病因。停用厄他培南后血小板计数恢复正常。医生识别并处理血小板增多症的病因至关重要,尤其是与药物相关的病因,以避免意外并发症并确保有效的患者护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02f7/10860918/494f9cc17c84/4283_Fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验